Cargando…

Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was us...

Descripción completa

Detalles Bibliográficos
Autores principales: Frison, Vera, Simioni, Natalino, Marangoni, Alberto, Balzano, Sara, Vinci, Carmela, Zenari, Luciano, De Moliner, Lorena, Tadiotto, Federica, D’Ambrosio, Michele, Confortin, Loris, Marin, Narciso, Lombardi, Simonetta, Costa, Silvana, Prosperini, Giuseppe, Lapolla, Annunziata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250628/
https://www.ncbi.nlm.nih.gov/pubmed/30238228
http://dx.doi.org/10.1007/s13300-018-0503-4
_version_ 1783372946934333440
author Frison, Vera
Simioni, Natalino
Marangoni, Alberto
Balzano, Sara
Vinci, Carmela
Zenari, Luciano
De Moliner, Lorena
Tadiotto, Federica
D’Ambrosio, Michele
Confortin, Loris
Marin, Narciso
Lombardi, Simonetta
Costa, Silvana
Prosperini, Giuseppe
Lapolla, Annunziata
author_facet Frison, Vera
Simioni, Natalino
Marangoni, Alberto
Balzano, Sara
Vinci, Carmela
Zenari, Luciano
De Moliner, Lorena
Tadiotto, Federica
D’Ambrosio, Michele
Confortin, Loris
Marin, Narciso
Lombardi, Simonetta
Costa, Silvana
Prosperini, Giuseppe
Lapolla, Annunziata
author_sort Frison, Vera
collection PubMed
description INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. RESULTS: Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by − 1.0 ± 1.2%, FPG levels by − 24.5 ± 43.4 mg/dl, body weight by − 5.3 ± 6.4 kg, systolic blood pressure by − 6.5 ± 18.5 mmHg, diastolic blood pressure by − 3.6 ± 11.8 mmHg, and total cholesterol by − 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels  of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in the 5- and 10-year risk of nonfatal CHD and fatal CHD were found, with no change in the 5- and 10-year risk of fatal and nonfatal stroke. CONCLUSION: In patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0503-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6250628
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-62506282018-12-07 Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study Frison, Vera Simioni, Natalino Marangoni, Alberto Balzano, Sara Vinci, Carmela Zenari, Luciano De Moliner, Lorena Tadiotto, Federica D’Ambrosio, Michele Confortin, Loris Marin, Narciso Lombardi, Simonetta Costa, Silvana Prosperini, Giuseppe Lapolla, Annunziata Diabetes Ther Original Research INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. RESULTS: Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by − 1.0 ± 1.2%, FPG levels by − 24.5 ± 43.4 mg/dl, body weight by − 5.3 ± 6.4 kg, systolic blood pressure by − 6.5 ± 18.5 mmHg, diastolic blood pressure by − 3.6 ± 11.8 mmHg, and total cholesterol by − 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels  of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in the 5- and 10-year risk of nonfatal CHD and fatal CHD were found, with no change in the 5- and 10-year risk of fatal and nonfatal stroke. CONCLUSION: In patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0503-4) contains supplementary material, which is available to authorized users. Springer Healthcare 2018-09-20 2018-12 /pmc/articles/PMC6250628/ /pubmed/30238228 http://dx.doi.org/10.1007/s13300-018-0503-4 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Frison, Vera
Simioni, Natalino
Marangoni, Alberto
Balzano, Sara
Vinci, Carmela
Zenari, Luciano
De Moliner, Lorena
Tadiotto, Federica
D’Ambrosio, Michele
Confortin, Loris
Marin, Narciso
Lombardi, Simonetta
Costa, Silvana
Prosperini, Giuseppe
Lapolla, Annunziata
Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title_full Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title_fullStr Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title_full_unstemmed Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title_short Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
title_sort clinical impact of 5 years of liraglutide treatment on cardiovascular risk factors in patients with type 2 diabetes mellitus in a real-life setting in italy: an observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250628/
https://www.ncbi.nlm.nih.gov/pubmed/30238228
http://dx.doi.org/10.1007/s13300-018-0503-4
work_keys_str_mv AT frisonvera clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT simioninatalino clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT marangonialberto clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT balzanosara clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT vincicarmela clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT zenariluciano clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT demolinerlorena clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT tadiottofederica clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT dambrosiomichele clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT confortinloris clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT marinnarciso clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT lombardisimonetta clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT costasilvana clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT prosperinigiuseppe clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy
AT lapollaannunziata clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy